The M&A machine that defined Q1 has carried directly into Q2 without missing a beat. Gilead Sciences announced a definitive agreement to acquire Munich-based Tubulis GmbH for up to $5 billion, adding a next-generation antibody-drug conjugate platform and two clinical-stage oncology candidates. This is Gilead’s third acquisition since late February—following Arcellx for $7.8 billion and Ouro Medicines for $2.18 billion—bringing the company’s total committed capital to approximately $15 billion across three deals in roughly six weeks. That is the most aggressive acquisition run in Gilead’s history. Hours earlier, Neurocrine Biosciences announced its largest acquisition ever, paying $2.9 billion for Soleno Therapeutics and its Vykat XR franchise in Prader-Willi syndrome—a rare disease drug that generated $190 million in its first year on the market with zero competition. AbbVie listed Humira on TrumpRx at a steep discount as the Section 232 tariff structure incentivizes exactly this behavior. And Foundayo continues its early rollout through LillyDirect as the oral GLP-1 war intensifies.
Top Story: Gilead’s $5B Tubulis Acquisition Caps a $15B Deal Spree
What Happened: Gilead Sciences announced a definitive agreement to acquire Tubulis GmbH for $3.15 billion upfront in cash plus up to $1.85 billion in milestone payments ($5 billion total potential value). The deal builds on a research collaboration the two companies established in December 2024. Tubulis will operate as a dedicated ADC research organization within Gilead, with Munich serving as a hub for ADC innovation. Close is expected in Q2 2026.
The Assets: Platform Plus Pipeline
Tubulis brings both clinical-stage candidates and proprietary technology that Gilead will use to build a broader ADC franchise.
The lead candidate, TUB-040, is a NaPi2b-directed topoisomerase-I inhibitor ADC currently in Phase 1b/2 development for platinum-resistant ovarian cancer and non-small cell lung cancer. At ESMO 2025, TUB-040 demonstrated a 59% overall response rate in platinum-resistant ovarian cancer—a notoriously treatment-resistant population where durable responses are rare. RBC Capital Markets called the data “validating a potentially novel target.”
The second clinical asset, TUB-030, is a 5T4-targeted ADC with promising early clinical data across various solid tumors. Beyond the pipeline, Gilead acquires Tubulis’s proprietary Tubutecan linker-payload technology, a next-generation ADC platform designed to improve stability and selectivity of payload delivery. This is not just a product acquisition—it is a platform acquisition that gives Gilead the tools to develop additional ADC candidates internally.
Tubulis raised €344 million ($401 million) in a Series C last October and also has an existing partnership with Bristol Myers Squibb. The company will maintain its Munich operations as a standalone research organization within Gilead, which reduces integration burden while adding geographic complexity to Gilead’s R&D footprint.
$15B in 6 Weeks: The Most Concentrated Deal Spree in Gilead’s History
The Tubulis acquisition must be understood in the context of the broader campaign Gilead has been executing since late February:
Arcellx (February): $7.8 billion for anito-cel, a next-generation CAR-T cell therapy for relapsed/refractory multiple myeloma. FDA decision expected H2 2026.
Ouro Medicines (March): $2.18 billion ($1.675 billion upfront plus $500 million in milestones) for gamgertamig (OM336), a BCMAxCD3 T-cell engager demonstrating “transformative efficacy” in autoimmune hemolytic anemia and immune thrombocytopenia after a single treatment cycle.
Tubulis (April): $5 billion for the ADC platform, TUB-040, and TUB-030.
Total: approximately $15 billion in committed capital across three deals building three distinct therapeutic franchises—cell therapy, autoimmune disease, and ADC oncology.
The Strategic Logic: Diversifying Beyond HIV and Hepatitis
The urgency behind this pace is defensive. Gilead’s HIV franchise is mature—still generating substantial revenue but with limited growth upside. Veklury (remdesivir) revenues have been declining since COVID case rates normalized. The company’s legacy hepatitis C franchise has been in structural decline for years. Without new growth drivers, Gilead faces long-term revenue erosion.
CEO Daniel O’Day has chosen to diversify through acquisition rather than relying solely on internal R&D, using Gilead’s substantial cash generation to buy pipeline and platforms across three distinct therapeutic areas. Each acquisition targets a different mechanism and a different commercial market, creating diversification at the portfolio level while concentrating execution risk in parallel integration workstreams.
The ADC space is particularly competitive. Daiichi Sankyo’s Enhertu franchise has established the gold standard for next-generation ADC development, and multiple companies—AstraZeneca, Pfizer, and others—are investing heavily in the category. Tubulis’s differentiation lies in its linker-payload chemistry, which aims to improve the therapeutic window of ADCs by delivering payloads more selectively to tumor cells while reducing off-target toxicity. Whether that differentiation proves clinically meaningful in registrational trials remains to be demonstrated.
Our Pro brief includes a full analysis of Gilead’s $15B deal spree, including the execution risk of running three major integrations simultaneously, how the Tubulis ADC platform compares to Daiichi Sankyo and AstraZeneca’s approaches, and what the Arcellx anito-cel FDA decision in H2 2026 means for the overall strategy. [Details below.]
What to Watch
The Arcellx anito-cel FDA decision in H2 2026 is the first major clinical milestone across Gilead’s three acquisitions. A positive outcome would validate the CAR-T leg of the strategy and provide a commercial revenue catalyst. For Tubulis, the TUB-040 Phase 1b/2 data in ovarian cancer will determine whether the 59% response rate from ESMO holds in a larger population and whether the NaPi2b target generates registrational-quality results. Watch whether Gilead signals appetite for a fourth acquisition or pivots to integration mode—the Tubulis deal will be financed with cash on hand and senior unsecured notes, and balance sheet capacity is not unlimited.
Neurocrine Pays $2.9B for Soleno and the Only Prader-Willi Drug
What Happened: Neurocrine Biosciences announced a definitive agreement to acquire Soleno Therapeutics for $53 per share in cash, a total equity value of $2.9 billion. The deal represents a 34% premium to Soleno’s closing price on April 2 and a 51% premium to the 30-day volume-weighted average price. This is Neurocrine’s largest acquisition in its 34-year history. SLNO shares surged 33% on the news. Close is expected within 90 days, funded with cash on hand and modest prepayable debt.
The Asset: A Monopoly in a Growing Rare Disease Market
Soleno’s Vykat XR (diazoxide choline) is the first and only FDA-approved treatment for hyperphagia in adults and children 4 years and older with Prader-Willi syndrome. PWS is a rare genetic disorder affecting approximately 10,000 people in the United States that causes compulsive, uncontrollable food-seeking behavior driven by hypothalamic dysfunction. Hyperphagia in PWS is not a behavioral problem—it is a neurological one, and without management it leads to life-threatening obesity and metabolic complications.
Vykat XR was approved in March 2025 and generated $190.4 million in 2025 revenue, including $92 million in Q4 alone. The drug swung Soleno into profitability in 2025 with $20.8 million in net income. Intellectual property extends into the mid-2040s. No direct competition exists for hyperphagia in PWS.
The Valuation Math
Neurocrine paid $2.9 billion for a drug generating approximately $190 million annually with a Q4 run rate suggesting $360 million or more in 2026 revenue. With IP protection extending roughly 20 years and no competitive threat on the horizon, the revenue stream is among the most predictable in rare disease.
CEO Kyle Gano called Vykat XR a drug with “all the profile aspects of a potential blockbuster in the making”—language that suggests Neurocrine’s internal projections significantly exceed current public estimates. The drug’s adoption trajectory—doubling from Q3 to Q4 in its launch year—supports the thesis that market penetration is still in early stages with substantial room for growth.
Strategic Fit: Neuroscience Meets Endocrinology
The acquisition positions Neurocrine at the intersection of neuroscience and metabolic disease. The company now holds three first-in-class medicines: INGREZZA (valbenazine for tardive dyskinesia), CRENESSITY (crinecerfont for congenital adrenal hyperplasia), and Vykat XR. Months before this deal, Neurocrine disclosed a preclinical obesity pipeline, signaling a broader metabolic strategy that the Soleno acquisition accelerates.
Prader-Willi syndrome sits at the crossroads of neurology and endocrinology—the hyperphagia is driven by hypothalamic dysfunction (neuroscience), but its consequences are metabolic (obesity, diabetes, cardiovascular risk). Neurocrine’s existing expertise in neurological drug development and its growing interest in metabolic disease make PWS a natural strategic fit.
Our Pro brief analyzes why Vykat XR’s monopoly position and accelerating adoption make the $2.9B price rational, how the drug’s revenue trajectory compares to other rare disease launches, and what the Soleno deal reveals about Neurocrine’s emerging metabolic franchise strategy. [Details below.]
What to Watch
Quarterly revenue trajectory for Vykat XR will be the primary metric post-close. The Q4 2025 acceleration to $92 million suggests adoption is compounding, but the sustainability of that growth rate in a 10,000-patient U.S. population will determine whether “potential blockbuster” becomes actual blockbuster. International expansion opportunities—PWS prevalence is global—could add meaningful revenue upside beyond the U.S. market.
Corporate Developments
AbbVie Lists Humira on TrumpRx at Steep Discount
AbbVie has listed Humira on TrumpRx, the administration’s direct-to-consumer drug pricing platform, at a steep discount. The move comes as the Section 232 tariff structure solidifies and companies seek to secure favorable tariff treatment through MFN pricing agreements.
Why This Matters: This is exactly the behavior the administration’s tariff framework was designed to produce. The 100% baseline tariff on patented pharmaceutical imports creates a powerful incentive for companies to make pricing concessions through TrumpRx and MFN agreements in exchange for the 0% rate. Humira, despite facing biosimilar competition, remains a multibillion-dollar franchise for AbbVie, and listing it at a discount on a government-sponsored platform is a clear signal that AbbVie is prioritizing tariff protection over list price preservation.
More companies are expected to follow AbbVie’s lead as the July 31 and September 29 tariff deadlines approach. The pattern from Q1 is now fully established: the administration proposes aggressive trade action, pharma companies resist initially, and then systematically capitulate through bilateral pricing and manufacturing agreements.
Foundayo Retail Rollout Continues
Lilly’s Foundayo (orforglipron) continues its early commercial rollout following last week’s FDA approval. LillyDirect shipping is active, and retail pharmacy and telehealth provider availability is expanding. The $149 per month self-pay pricing at the lowest dose positions Foundayo as the most accessible branded oral GLP-1 on the market alongside Novo’s Wegovy pill at the same entry price point. Early prescription volume data—expected in the coming weeks—will provide the first competitive signal in the oral GLP-1 head-to-head battle.
Strategic Themes
1. Gilead Is Building a Company Through Acquisition at Unprecedented Speed
$15 billion across three deals in six weeks is not a normal M&A pace—it is a corporate transformation executed in real time. Gilead is systematically constructing three new therapeutic franchises (cell therapy, autoimmune, ADC oncology) to diversify beyond its maturing HIV base. The strategy is sound in concept, but the execution risk is substantial. Running three major integrations simultaneously—spanning California, Munich, and the Galapagos collaboration—tests organizational bandwidth in ways that deal announcements do not capture. The Arcellx FDA decision in H2 2026 will be the first real test of whether the acquired assets deliver clinical returns on the capital deployed.
2. Monopoly Products in Rare Disease Command Premium Valuations—and Deserve Them
Neurocrine’s $2.9 billion for Vykat XR illustrates a simple but powerful principle: a first-in-class drug with no competition, accelerating adoption, and 20 years of IP protection is worth paying a premium for. The 34% headline premium understates the strategic value because Soleno’s pre-deal stock price already reflected the strong commercial launch. In rare disease, monopoly economics are durable in ways that competitive markets are not—there is no biosimilar threat, no head-to-head trial to lose, and no pricing pressure from therapeutic alternatives. For acquirers with the capital, these are the most predictable revenue streams in all of pharma.
3. The Section 232 Tariff Framework Is Producing Exactly the Behavior It Was Designed to Produce
AbbVie listing Humira on TrumpRx at a steep discount is not a voluntary pricing decision—it is a direct response to the 100% tariff threat on patented pharmaceutical imports. The administration constructed a framework where companies that make pricing concessions and manufacturing commitments pay 0%, and companies that do not pay 100%. The result is predictable: every major pharma company is moving toward the 0% tier by meeting the administration’s conditions. Whether this represents genuine price reform or performative compliance is debatable. What is not debatable is that the framework is functioning as designed.
4. The Q2 M&A Pace Is Already Matching Q1’s Intensity
Gilead/Tubulis ($5 billion) and Neurocrine/Soleno ($2.9 billion) bring Q2’s first-week deal total to nearly $8 billion, on top of the $46.8 billion deployed in Q1. Jefferies’ projection that 2026 could reach $172 billion in total M&A is looking increasingly realistic. BMO identified AbbVie ($33.6 billion in capacity), BMS ($21.9 billion), and Amgen ($18.6 billion) as companies that have been conspicuously quiet relative to their pipeline needs. If any of these enter the market with a major deal in the coming weeks, Q2 will match or exceed Q1’s pace.
Frequently Asked Questions
How much has Gilead spent on acquisitions in 2026?
Approximately $15 billion across three deals since late February: Arcellx for $7.8 billion (CAR-T, February), Ouro Medicines for $2.18 billion (autoimmune T-cell engager, March), and Tubulis for up to $5 billion (ADC oncology, April). This is the most concentrated acquisition period in Gilead’s history, building three new therapeutic franchises simultaneously.
What is Tubulis, and why does it matter for Gilead’s oncology strategy?
Tubulis is a Munich-based biotech developing next-generation antibody-drug conjugates. Its lead candidate TUB-040 showed a 59% response rate in platinum-resistant ovarian cancer at ESMO 2025. Beyond the pipeline, Gilead acquires the proprietary Tubutecan linker-payload technology, a platform for developing additional ADC candidates. Tubulis will operate as a standalone ADC research organization within Gilead.
What is Vykat XR, and why did Neurocrine pay $2.9B for it?
Vykat XR is the first and only approved treatment for hyperphagia in Prader-Willi syndrome, a rare genetic disorder affecting approximately 10,000 people in the U.S. The drug generated $190 million in its first year on market with $92 million in Q4 alone, suggesting a 2026 run rate above $360 million. With no competition, IP extending to the mid-2040s, and accelerating adoption, the revenue stream is among the most predictable in rare disease.
Why is AbbVie listing Humira on TrumpRx?
The Section 232 tariff structure imposes 100% tariffs on patented pharmaceutical imports but offers a 0% rate for companies with MFN pricing agreements and onshoring commitments. Listing Humira on TrumpRx at a steep discount is part of AbbVie’s strategy to secure favorable tariff treatment. The framework is designed to incentivize exactly this behavior—pricing concessions in exchange for tariff exemptions.
How does Gilead’s deal spree compare to other pharma companies in 2026?
Gilead’s $15 billion across three deals in six weeks is the most concentrated acquisition period for any single company in 2026. For comparison, Lilly committed approximately $11 billion across three deals (Morphic, Insilico, Centessa) over a longer period. Novartis made two deals totaling $5 billion. Gilead’s pace stands out for both the total capital deployed and the compressed timeline.
What is the competitive landscape for ADCs?
Daiichi Sankyo’s Enhertu franchise has established the gold standard for modern ADC development. AstraZeneca, Pfizer, and multiple other companies are investing heavily in the category. Tubulis’s differentiation lies in its linker-payload chemistry designed to improve payload delivery selectivity. Whether that technology translates to a clinically meaningful advantage over existing ADC platforms will be determined in registrational trials.
How is the Foundayo launch progressing?
LillyDirect shipping is active and retail pharmacy availability is expanding. Self-pay pricing starts at $149 per month at the lowest dose. Early prescription volume data, expected in the coming weeks, will provide the first competitive signal against Novo’s oral Wegovy, which launched in January and is priced at the same $149 entry point.
What M&A capacity remains among major pharma companies?
BMO identified AbbVie ($33.6 billion), BMS ($21.9 billion), and Amgen ($18.6 billion) as companies with significant remaining acquisition capacity. Novartis has over $50 billion in capacity despite two Q1 deals. These companies have been relatively quiet compared to Gilead and Lilly, and any entry into the market with a major deal would sustain or accelerate the current M&A pace.
BioMed Nexus Pro — What Institutional Subscribers Are Reading Today
Gilead’s $15B Deal Spree: Transformation or Overextension? We analyze the strategic logic of building three therapeutic franchises simultaneously through acquisition, assess the execution risk of parallel integrations across California, Munich, and the Galapagos collaboration, and frame the Arcellx anito-cel FDA decision in H2 2026 as the first major test of the strategy.
Neurocrine’s Blockbuster Bet: The Rare Disease Monopoly Math. We break down why Vykat XR’s $190M first year, accelerating adoption curve, zero competition, and 20-year IP runway make the $2.9B price rational, and model the revenue trajectory under conservative and bull-case adoption scenarios.
Q2 M&A Running Tally: Nearly $8B in Week One. We compile the deals, track the remaining acquisition capacity across major pharma companies, and assess which therapeutic areas and mechanisms are attracting the most capital as the M&A supercycle continues.
Plus: Foundayo launch monitoring, Section 232 tariff compliance tracking, retatrutide mid-year preview, and the updated catalyst calendar through H2 2026.
About BioMed Nexus
BioMed Nexus delivers institutional-grade intelligence to biotech and pharma executives, investors, and clinicians. Our daily briefings and deep-dive analyses cut through the noise to deliver the strategic insights that drive better decision-making in the life sciences.
Subscribe to receive daily updates and gain access to BioMed Nexus Pro institutional intelligence briefs.
